Beijing Biostar Pharms Co Ltd
2563.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.04B
Close$
$-1.55
138.9% downside
Current Fair Value
138.9% downsideOvervalued by 138.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.04 Billion |
|---|---|
| Enterprise Value | $524.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | -0.17 |
| Outstanding Shares | 364,592,416 |
Return
| Return on Equity | -16.86% |
|---|---|
| Return on Assets | -14.56% |
| Return on Invested Capital | -15.07% |
Valuation & Multiples
| P/E Ratio | -12.51 |
|---|---|
| PEG | 23.8 |
| Price to Sales | - |
| Price to Book Ratio | 2.0 |
| Enterprise Value to Revenue | 8.13 |
| Enterprise Value to EBIT | -4.45 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Beijing Biostar Pharms Co Ltd
134 employees
CEO: Rongguo Qiu Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent...